Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 11/20 | 0.59 |
| ▸ | GABRB3 | P28472 | 11/20 | 0.59 |
| ▸ | GABRA5 | P31644 | 11/20 | 0.59 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.58 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.58 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.58 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.54 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | HTR1D | P28221 | 1/20 | 0.49 |
| ▸ | HTR1B | P28222 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7634522 | 0.84 | GABRG2 (0.62) | GABRG2GABRB3GABRA5GABRA2GABRA1 | |
| SCHEMBL8866535 | 0.83 | ALDH1A1 (0.48) | GABRG2GABRB3GABRA5GABRA2GABRA1 | |
| SCHEMBL14321045 | 0.82 | HTR1A (0.55) | GABRG2GABRB3GABRA5GABRA2GABRA1 | |
| SCHEMBL2236417 | 0.81 | GABRG2 (0.60) | GABRG2GABRB3GABRA5GABRA2GABRA1 | |
| SCHEMBL430171 | 0.79 | HTR1A (0.51) | GABRG2GABRB3GABRA5GABRA2GABRA1 | |
| SCHEMBL2233500 | 0.79 | GABRG2 (0.58) | GABRG2GABRB3GABRA5GABRA2GABRA1 | |
| SCHEMBL426964 | 0.79 | HTR1A (0.58) | GABRG2GABRB3GABRA5GABRA2GABRA1 | |
| SCHEMBL430212 | 0.78 | HTR1A (0.57) | GABRG2GABRB3GABRA5GABRA2GABRA1 | |
| SCHEMBL427036 | 0.78 | HTR1A (0.62) | GABRG2GABRB3GABRA5GABRA2GABRA1 | |
| SCHEMBL13002475 | 0.78 | GABRG2 (0.57) | GABRG2GABRB3GABRA5GABRA2GABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0625982-B1 | 4-OXO- AND 4H-IMIDAZO(5,1-C)(1,4)BENZOXAZINES USEFUL AS BENZODIAZEPINE RECEPTOR-BINDING AGENTS | UPJOHN CO (US) | 2002-06-12 | — | — | EP | claimed |
| US-4880799-A | CENTRAL NERVOUS SYSTEM DISORDERS, ANTICONVULSANTS | A/S FERROSAN (DK) | 1989-11-14 | — | — | US | claimed |
| US-20110213143-A1 | COMPOUND HAVING TAFIA INHIBITORY ACTIVITY | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-09-01 | — | — | US | disclosed |
| EP-2361910-A1 | COMPOUND HAVING TAFIA INHIBITORY ACTIVITY | Taisho Pharmaceutical Co., Ltd. (JP) | 2011-08-31 | — | — | EP | disclosed |
| EP-0625982-B1 | 4-OXO- AND 4H-IMIDAZO(5,1-C)(1,4)BENZOXAZINES USEFUL AS BENZODIAZEPINE RECEPTOR-BINDING AGENTS | UPJOHN CO (US) | 2002-06-12 | — | — | EP | disclosed |
| US-5610158-A | ANXIOLYTIC AGENTS, SEDATIVES | THE UPJOHN COMPANY (US) | 1997-03-11 | — | — | US | disclosed |
| EP-0625982-A1 | 4-OXO- AND 4H-IMIDAZO(5,1-C)(1,4)BENZOXAZINES USEFUL AS BENZODIAZEPINE RECEPTOR-BINDING AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 1994-11-30 | — | — | EP | disclosed |
| WO-1993016082-A1 | 4-OXO- AND 4H-IMIDAZO(5,1-C)(1,4)BENZOXAZINES USEFUL AS BENZODIAZEPINE RECEPTOR-BINDING AGENTS | THE UPJOHN COMPANY (US) | 1993-08-19 | — | — | WO | disclosed |
| US-4886797-A | CENTRAL NERVOUS SYSTEM DISORDERS | A/S FERROSAN (DK) | 1989-12-12 | — | — | US | disclosed |
| US-4880799-A | CENTRAL NERVOUS SYSTEM DISORDERS, ANTICONVULSANTS | A/S FERROSAN (DK) | 1989-11-14 | — | — | US | disclosed |
| US-4870073-A | CENTRAL NERVOUS SYSTEM DISORDERS, ANTHELMINTICS, PARASITICIDES, INSECTICIDES | A/S FERROSAN (DK) | 1989-09-26 | — | — | US | disclosed |
| EP-0220845-A1 | Heterocyclic compounds and their preparation and use | A/S FERROSAN (DK) | 1987-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110213143-A1 | COMPOUND HAVING TAFIA INHIBITORY ACTIVITY | TAF1, TAF5, TAF11 | GABRG2 2731/4885GABRB3 1763/4885GABRA5 1685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.